Our News

Our companies and we are trying to stay at forefront of innovation with the goal to save and improve patients' lives. We are glad to share our progress on the way to achieving this goal.

November 2020

AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

November 2020

ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01

November 2020

Pureos Bioventures invests in seed financing of Corlieve Therapeutics SAS to develop therapies for severe neurological conditions

October 2020

Araris Biotech Completes CHF 15.2 Million Seed Financing Round

October 2020

ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Annual Meeting

September 2020

Johnson & Johnson Innovation renews its commitment to BaseLaunch Phase II

September 2020

Pureos Bioventures closes first fund with USD 170 mn

September 2020

NovaGo Therapeutics appoints Ian Metcalfe as CEO

September 2020

Pureos invests in EUR 71 million financing of LAVA Therapeutics

July 2020

Pureos invests in EUR 27 million Series A financing of Vico Therapeutics

July 2020

Bridge Biotherapeutics becomes BaseLaunch’s first Asia Pacific partner

June 2020

BB Pureos Bioventures expands its advisory board by appointing Dr. Omar Khwaja

June 2020

With Roivant Sciences another partner has joined BaseLaunch Phase II

June 2020

BB Pureos Bioventures joins BaseLaunch Phase II as the first venture capital fund

May 2020

"Das Coronavirus wird in der Zivilisation bleiben." Interview mit Klaus Breiner in der Engadiner Post.

April 2020

BB Pureos Bioventures expands its team of Partners and Entrepreneurs with the appointment of Dr. Anja Harmeier

January 2020

Eyevensys Closes USD 30 mn Series B Financing

July 2019

AM-Pharma raises EUR 116 mn to conduct pivotal Phase III Trial of recAP in Acute Kidney Injury

April 2019

BB Pureos Bioventures (Pureos) co-led a CHF 12.5 mn investment in Alentis Therapeutics AG

March 2019

NovaGo Therapeutics raises CHF 10 mn to develop regenerative anti-Nogo therapy for stroke

June 2018

Hochkarätiger Beirat für neue Risikokapitalgesellschaft BB Pureos Bioventures

May 2018

NZZ.ch - Fünf Fragen an Dominik Escher

April 2018

NZZ.ch - Im Biotech-Sektor klafft eine Finanzierungslücke

February 2018

Agéfi - Pureos Bioventures se focalise sur les biotechs actives dans la recherche de médicaments

February 2018

Initative for venture capital in Switzerland